[Cancer of the prostate: estrogen therapy]

From 1941, estrogens are usually used in the treatment of prostatic carcinoma, wrongly in case of adjuvant hormonotherapy and exceedingly because of cardiovascular toxicity from over dosages. A recall of their mechanism of action and toxicity allows to argue about the palliative treatment and to look to their use for the locally advanced cancers in order to get a tumoral reduction before radiotherapy. A pilot study realised by the authors shows that this hormono-radiotherapic protocol is achievable.